Nov 20, 2023
MediSieve Welcomes Dr. Alessandro Falcone as New Board Member
MediSieve announces Dr. Alessandro Falcone, with a distinguished background in Oncology R&D at AstraZeneca and previous roles at GSK and Novartis, as its new board member.
LONDON, November 20, 2023 – MediSieve announced the appointment of Dr. Alessandro Falcone as its newest board member. Dr. Falcone brings a wealth of experience from his illustrious career in Oncology R&D at AstraZeneca, coupled with significant roles at pharmaceutical giants GSK and Novartis.
Dr. Falcone's expertise extends over a decade in R&D and commercial positions within the life sciences sector. His prior experience includes impactful roles at LEK and IQVIA, where he focused on investments in life science. His academic credentials are equally impressive, holding an MD from University College London (UCL), a B.Sc. in Business & Healthcare Management from Imperial College London, and a M.Sc. in Experimental & Translational Therapeutics from the University of Oxford.
“We are thrilled to welcome Dr. Falcone to our board,” said MediSieve's CEO, Dr George Frodsham. “His exceptional track record in the pharmaceutical industry and his profound knowledge in healthcare management and therapeutics will be invaluable to MediSieve. Dr. Falcone’s industry experience and insights will undoubtedly contribute to our strategic direction and growth.”
Dr. Falcone's appointment comes at a crucial time as MediSieve continues to advance in the field of Magnetic Blood Filtration. His guidance and expertise are expected to play a pivotal role in the company’s ongoing projects and future endeavours. This new appointment signifies MediSieve’s commitment to strengthening its leadership with experts who bring a diverse range of experiences and perspectives, crucial for driving innovation in the healthcare industry.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Capture System captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: